CDC has updated its Oropouche virus resources to reflect findings from a Brazilian study indicating a link between Oropouche virus and congenital malformations, with six infants testing positive for antibodies despite some mothers showing no symptoms. Routine testing for asymptomatic patients is not recommended. However, health care providers should consult local health departments if a pregnant individual has traveled to affected areas and shows concerning fetal findings or experiences stillbirth. Health departments can coordinate testing and CDC consultations.
- Updated Interim Guidance for Health Departments on Testing and Reporting for Oropouche Virus Disease
- Interim Guidance for Evaluating and Managing Infants Born to Pregnant People with Confirmed or Probable Oropouche Virus Disease
- Interim Clinical Considerations for Pregnant People with Confirmed or Probable Oropouche Virus Disease
In addition, the Oropouche Level 1 travel health notice (THN) now includes Ecuador, Bolivia, Brazil, Colombia, Dominican Republic, Guyana, and Peru. The updated Level 1 notice also adds language reflecting CDC’s current recommendations regarding the risk of sexual transmission of Oropouche.